May #81 : Seattle Rattle - by Mike Barr

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Divinely Driven Dick

The Doctor Is Out

Say Aaaaah!

Unveiled

HMOs & HIV

Loan Ranger

Raging Bull

Global Yodel

Bush 2, MaryJane 0

Milestones

Afghan AIDS

Hemo Hero

Georgia on My Mind

I Want My HIV TV

Jock Sock

Gal-lery

Spin Cycle

Seattle Rattle

Prime Time

Rhesus in Pieces

Fast Lane T Cells

Sustiva Diva

Coke Is It

Obituary

Marathon Man

Love Handles

Publisher's Letter

Mailbox

Playing (for Keeps) in Poughkeepsie

AZT Ace

NEG/POS



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

May 2002

Seattle Rattle

by Mike Barr

By the close of the wonkish wonderland in Seattle known as the 9th-annual Conference on Retroviru

By the close of the wonkish wonderland in Seattle known as the 9th-annual Conference on Retroviruses and Opportunistic Infections, 2002 had been hailed as The Year of the Entry Inhibitors (EIs). Imagine an entirely new strategy to attack HIV. Are happy days here again?

Nearing the finish line first is Trimeris/Roche's EI, T-20. In a one-year study of T-20 in combo with HAART, half of 50 pre-treated and 70 untreated HIVers saw their viral load disappear below 400. Both Schering-Plough and Bristol-Myers Squibb (BMS) showcased their EIs, too. Along with T-20, these three compounds represent three unique approaches to blocking HIV from entering (duh!) a cell: docking, attachment and fusion. First, HIV sinks its gp120 protein spike into your cell's CD4 receptor. Second, HIV hooks onto one of the "co-receptors," such as CCR5. Third, HIV "fuses" with the cell to insert its RNA.

BMS' aptly named BMS-806 targets the first step of the entry process, altering the structure of the gp120 spike to prevent it from latching onto a CD4 cell. While BMS is gushing over its test-tube data, human tests -- set for this year -- will be the acid test.

Schering's EI, SCH-C, has made it that far. SCH-C is a molecule that inhibits the second stage of entry: It glomms onto a cell's CCR5 co-receptors and mucks up viral attachment. In a preliminary eight-week study, SCH-C used alone in 12 pre-treated patients reduced viral load by two-thirds in 10 of them.

T-20 blocks the final step of HIV entry: fusion with the cell and insertion of viral genes. T-20 (and its sister T-1249) have previously shown a potent punch against drug-resistant HIV, with relatively little toxicity. Trimeris hopes for the FDA stamp of approval later this year.

In addition to the EIs with their docking, attachment and fusion targets, the Retrovirus pageant debuted the first human data on a fourth new strategy: integrase inhibitors (IIs), which gum up the machinery of the HIV integrase gene. This important gene, so named because it incorporates, or "integrates," HIV into your cell's genes, remains a fast-moving target. An earlier II gave a stellar performance in the test tube but bombed in humans. Still, hopes are high for two new IIs -- Shionogi's S-1360, which recently moved into human studies, and Merck's L-708,906, set to enter Phase I human trials in March.




[Go to top]

Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV 101
HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
Disclosing Your Status
Starting Treatment
Search for the Cure
POZ Stories
POZ TV
Read the Blogs
Visit the Forums
Women
African American
Latino
Providers
Job Listings
Events Calendar


    charliehunter
    San Francisco
    California


    Sin_Grinder
    Reno
    Nevada


    youngbloodlatino
    Columbia
    Maryland


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Do you enjoy books with HIV-positive characters?
Yes
No

Survey
Mind Matters

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.